News MHRA gives Alnylam 'innovation passport' for hypertension dr... The UK medicines regulator has awarded Alnylam's RNAi-based therapy zilebesiran for hypertension an 'innovation passport', a
News MHRA grants bluebird 'innovation passport' for sickle cell t... bluebird bio's sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an 'innovation passport' introduced in the UK earlier this year to speed up NHS access to promisi
News Novo Nordisk sheds billions in value on obesity data Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
